Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

BioXcel Therapeutics, Inc. (BTAI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/10/2023 SC 13G/A FIL Ltd reports a 9.2% stake in BIOXCEL THERAPEUTICS INC
10/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer",
"Astria Therapeutics October 2023 1 Exhibit 99.2 Cautionary Note Regarding Forward Looking Statements and Disclaimer This"
10/04/2023 8-K Regulation FD Disclosure  Interactive Data
09/28/2023 SC 13D BioXcel LLC reports a 32.5% stake in BioXcel Therapeutics, Inc.
08/22/2023 8-K Other Events  Interactive Data
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization"
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/29/2023 8-K Other Events  Interactive Data
06/28/2023 4 Bray June (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Granted 17,000 options to buy @ $17.52, valued at $297.8k
06/28/2023 4 MUELLER PETER (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Granted 17,000 options to buy @ $17.52, valued at $297.8k
06/28/2023 4 MILLER MICHAEL PATRICK (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Granted 17,000 options to buy @ $17.52, valued at $297.8k
06/28/2023 4 Laumas Sandeep (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Granted 17,000 options to buy @ $17.52, valued at $297.8k
06/28/2023 4 Votruba Michal (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Granted 17,000 options to buy @ $17.52, valued at $297.8k
Disposed of 17,000 options to buy @ $17.52, valued at $297.8k
06/16/2023 4 Rodriguez Javier (See Remarks) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Exercised 521 restricted stock units @ $0
06/16/2023 4 Yocca Frank (Chief Scientific Officer) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Exercised 521 restricted stock units @ $0
06/16/2023 4 Steinhart Richard I (CFO) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Exercised 521 restricted stock units @ $0
06/16/2023 4 Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Sold 21,988 shares @ $21.41, valued at $470.8k
Sold 8,012 shares @ $21.9, valued at $175.5k
Sold 24,987 shares @ $20.01, valued at $500k
Sold 4,266 shares @ $20.9, valued at $89.2k
Sold 747 shares @ $21.89, valued at $16.4k
Exercised 2,609 restricted stock units @ $0
Exercised 30,000 options to buy @ $0.41, valued at $12.3k
Exercised 30,000 options to buy @ $0.41, valued at $12.3k
06/16/2023 4 O'Neill Vincent (Chief Medical Officer) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Exercised 521 restricted stock units @ $0
05/24/2023 4 Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Sold 6,500 shares @ $25.7909, valued at $167.6k
05/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/16/2023 4 Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Exercised 15,000 restricted stock units @ $0
05/16/2023 4 Steinhart Richard I (CFO) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Sold 5,000 shares @ $27.1727, valued at $135.9k
Exercised 5,000 restricted stock units @ $0
05/16/2023 4 Rodriguez Javier (See Remarks) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns: Sold 1,785 shares @ $27.3192, valued at $48.8k
Exercised 5,000 restricted stock units @ $0
05/16/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/20/2023 8-K Quarterly results
04/14/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy